2020.04
TSH Biopharm launches Guzip’s Mpap Test, a new endometrial cancer screening test
2019.12
TSH Biopharm awarded for the 16th National Innovation Prize in Entrepreneur Category
2019.08
TSH sunmitted new drug application (NDA) for RNTA06 to TFDA
2019.07
TSH Biopharm authorize InnoPharmax reauthorize the third party to commercialize CRTA
2019.06
The Bridging study of RNTA06, which is indicated for the treatment of chronic angina, is completed and unblended, and the result meets the primary endpoint
2019.03
Invested in the US company CellMax Cayman and signed a distribution contract withits subsidary CellMax Life (hereafter referred to as CellMax Life) to acquire the exclusive commercialization right of all CellMax Life liquid- biopsy diagnosis products and subsequent new products in territory of Taiwan
2017.07
TuNEX (ENIA or ENIA11 or E11)  has been approved by TFDA
2016.12
TSH sunmitted new drug application (NDA) for CRTA04 to TFDA
2016.07
TSH sunmitted new drug application (NDA) for RNTA06 to TFDA
2016.06
The second Phase III clinical trial of E11 (TuNEX) was unblinded
2016.04
TSH sunmitted new drug application (NDA) for E11 (TuNEX) to TFDA
2016.03
The first Phase III clinical trial of E11 (TuNEX) was unblinded
2016.02
The Investigational New Drug (IND) application for E11 (TuNEX) ankylosing spondylitis Phase III clinical study is approved by TFDA
2015
DM07 hypertension treatment indication patent are granted in China, Japan, and Russia
2015.08
Patient recruitment of E11(TuNEX) phase III clinical study is completed
2014.09
TSH is granted by Taiwan Corporate Governance Association for CG6009 Company Management Assessment Certification
2014.08
TRIA11 is granted by Ministry of Economic Affairs A+ Industrial Innovative R&D Fund program for osteoporosis treatment  
2014.06
TSH invests Pharmira Laboratories, Inc. NTD 70 million and obtains 31.82% share 
2013.09
TSH raises NTD 34.9 million and makes Paid-in capital to NT$383 million
2013.08
TSH ENIA11 is granted by Ministry of Economic Affairs Industrial Technology Development Fund Program for Phase III Clinical Study
2012.12
TSH initiates ENIA11 PhaseIII Clinical Trial
2012.09
TSH Amtrel wins 2012 Taipei Biotechnology Commercialization Award
2012.09
EMTA07 and ENIA11 are named as the Demonstration Projects of DFTA Pharm Development of Taiwan and China Program
2012.08
TSH Linicor is approved by TFDA for Hyperlipidemia
2012.04
TSH raises NTD 37.34 million and makes Paid-in capital to NTD 317 million
2012.04
TSH is approved for OTC (Over the Counter) company 
2011.09
TSH applies for OTC (Over the Counter) company registration 
2011.06
TSH is approved and registered in Emerging stock market list
2011.03
TSH is approved by Financial Supervisory Commission as Public Offering Stock
2010.09
TSH raises NTD 30 million and makes Paid-in capital to NTD 280 million
2010.09
TSH Biopharm spin-off from TTY Biopharm, with a paid-in capital of NT$150 million
2010.01
Amtrel formulations patent granted
2009.01
Catilon is launched for the treatment of irritable bowel syndrome
2007.03
Amtrel is launched for hypotension 
2006.04
Mopride is launched for the treatment of functional dyspepsia
2003.09
TTH Business Unit is established in TTY Biopharm and focusing on Cardiovascular, Gastrointestinal, and Central nervous system diseases